Inetetamab

伊尼妥单抗

Report date: 2025/03/07 18:01:12

Base Information

Drug NameInetetamab

Drug Alias Name重组抗HER2人源化单抗（三生国健）Cipterbin赛普汀CMAB-302302H +[6]

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized

Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulantsReceptor protein-tyrosine kinase erbB-2 antagonists

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsMetastatic breast cancerBreast Neoplasms

Global Approved IndicationsBreast Neoplasms

Approved Indications in ChinaBreast Neoplasms

Original Approved Country/TerritoryMainland China

Original Approved Date2020/06/17

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusApproved

Highest Status in ChinaApproved

Originator CompaniesSunshine GuoJian Pharmaceutical (Shanghai) Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesSunshine GuoJian Pharmaceutical (Shanghai) Co Ltd Chengdu Scimount Pharmatech Co Ltd

Inactive CompaniesN/A

Active IndicationsBreast Neoplasms

Inactive IndicationsMetastatic breast cancer

Other Information

ATC CodeL01XC